Evonik Industries AG has announced a new investment at Evonik Rexim (Nanning) Pharmaceutical Co. Ltd. for an active pharmaceutical ingredients plant. A groundbreaking ceremony for this investment was held on November 21.

Evonik Rexim (Nanning) Pharmaceutical Co. Ltd. was originally established by Evonik Industries (previously known as Degussa AG) and its local partners in 2001. In 2005, Evonik Rexim became one of the wholly owned subsidiary companies of Evonik Industries. The company now has about 300 employees. Its main products are cGMP (current Good Manufacturing Practices) controlled pharmaceutical amino acids for the domestic and for export markets.

This new cGMP Amino Acid Derivatives plant will produce large scale APIs for global pharmaceutical customers of Evonik’s business line Exclusive Synthesis & Amino Acids. Evonik Degussa has been chosen as a supplier under a long-term contract because it has custom manufacturing assets in Europe and in China. This gives the customers a unique combination of a competitive cost position, an excellent track record in audits by Western and Chinese health authorities, and IP protection systems. The new plant is scheduled to be put into operations during the fourth quarter. With this investment Evonik Rexim will be able to provide approximately 100 new working opportunities for the local economy development in Nanning.

Evonik Industries is the creative industrial group from Germany that operates in three business areas: chemicals, energy, and real estate. Evonik is a global leader in specialty chemicals, an expert in power generation from hard coal and renewable energies, and one of the largest private residential real estate companies in Germany. Evonik is active in more than 100 countries around the world.